ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

fludarabine

Also written as “Fludarabine”, “Cyclophosphamide,Fludarabine” and “TC-D101 CAR-T”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Multiple Myeloma · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Lymphoma, Non-Hodgkin · Glioblastoma, led by 18 companies.

Drug pageFludarabine: every studyMany companies study it; this page follows only the 35 they lead. All 745 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 5, 202635 company-led studies, 21 open or runningNext primary completion: Jan 14, 2027 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Biotechits history only99 open or runningphase 2since Apr 5, 2026Mar 14, 2026Feb 18, 2027phase 1 · NCT07480941
Hoffmann-La Rocheits history only60 open or runningphase 4since Jan 4, 2011Oct 16, 2007none ahead
Allogene Therapeuticsits history only32 open or runningphase 2since Dec 8, 2022Dec 8, 2022Dec 2027phase 2 · NCT06500273
Hangzhou Huasai Biomedicineits history only22 open or runningphase 1since Jul 22, 2025Jul 22, 2025Aug 30, 2027phase 1 · NCT07105176
Shanghai First Song Biotechnologyits history only21 open or runningearly phase 1since Jul 30, 2024Jul 30, 2024none ahead
Adicet Therapeuticsits history only10 open or runningphase 1since Jan 26, 2021Jan 26, 2021none ahead
Biotech Equity Partners Ptyits history only10 open or runningphase 1since Feb 20, 2008Feb 20, 2008none ahead
Bristol-Myers Squibbits history only11 open or runningphase 1since Feb 7, 2025Feb 7, 2025Mar 15, 2029phase 1 · NCT07115745
Caribou Biosciencesits history only11 open or runningphase 1since Nov 16, 2020Nov 16, 2020none ahead
CARsgen Therapeuticsits history only10 open or runningphase 1since Aug 9, 2016Aug 9, 2016none ahead

Also a collaborator on its studies: Natera.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 15 studies since Oct 16, 2007.

  1. Feb 5, 2023Shanghai Ming Ju Biotechnology’s first study: phase 1 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNew to Shanghai Ming Ju BiotechnologyShanghai Ming Ju Biotechnology · NCT05727683 · 33 planned · China
  2. Jun 26, 2024Phase 2 study in Lymphoma, Large B-Cell, DiffuseAllogene Therapeutics · NCT06500273 · 250 planned · United States, Australia, Canada and more
  3. Jul 30, 2024Shanghai First Song Biotechnology’s first studies: 2 early phase 1 studiesNew to Shanghai First Song BiotechnologyShanghai First Song Biotechnology · NCT06532643, NCT06532630
  4. Feb 7, 2025Bristol-Myers Squibb’s first study: phase 1 study in Autoimmune DiseasesNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT07115745 · 125 planned · United States, Australia, Brazil and more
  5. Jul 8, 2025Phase 1 study in Lupus Erythematosus, SystemicAllogene Therapeutics · NCT07085104 · 66 planned · United States, Canada
  6. Jul 22, 2025Hangzhou Huasai Biomedicine’s first study: phase 1 study in Advanced Non-Small Cell Lung CancerNew to Hangzhou Huasai BiomedicineHangzhou Huasai Biomedicine · NCT07105176 · 12 planned · China
  7. Aug 19, 2025Neukio Biotherapeutics (Shanghai)’s first study: early phase 1 study in AutoimmuneNew to Neukio Biotherapeutics (Shanghai)Neukio Biotherapeutics (Shanghai) · NCT07144462 · 8 planned · China
  8. Aug 25, 2025Johnson & Johnson’s first study: phase 2 study in Multiple MyelomaNew to Johnson & JohnsonJohnson & Johnson · NCT07149857 · 60 planned · United States, Australia, Spain
  9. Nov 17, 2025TCRCure Biopharma’s first study: early phase 1 study in Small Cell Lung CarcinomaNew to TCRCure BiopharmaTCRCure Biopharma · NCT07246304 · 24 planned · China
  10. Mar 14, 2026Beijing Biotech’s first studies: 2 phase 1 studiesNew to Beijing BiotechBeijing Biotech · NCT07480941, NCT07492628
  11. Apr 5, 20264 phase 2 studiesPhase 2 reachedBeijing Biotech · NCT07523542, NCT07523529, NCT07551362 and 1 more
  12. Apr 18, 2026Phase 1 study in GliomaBeijing Biotech · NCT07551336 · 36 planned · China
  13. May 14, 20262 phase 2 studiesBeijing Biotech · NCT07598955, NCT07617805
  14. Sep 15, 2026Phase 1 study in Advanced NSCLCHangzhou Huasai Biomedicine · NCT07830342 · 24 planned · China

Ahead

  1. Jan 14, 2027Primary completion: early phase 1 study in AutoimmuneNeukio Biotherapeutics (Shanghai) · NCT07144462
  2. Feb 18, 2027Primary completion: phase 1 study in GlioblastomaBeijing Biotech · NCT07480941
  3. Mar 14, 2027Primary completion: phase 2 study in RecurrenceBeijing Biotech · NCT07617805
  4. Mar 14, 2027Primary completion: phase 2 study in Stomach NeoplasmsBeijing Biotech · NCT07551362

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 35 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07830342Advanced NSCLC · China1RecruitingHangzhou Huasai BiomedicineOct 202824
NCT07617805Recurrence · China2RecruitingBeijing BiotechMar 14, 202742
NCT07598955Thymoma · China2RecruitingBeijing BiotechJun 14, 202736
NCT07551362Stomach Neoplasms · China2RecruitingBeijing BiotechMar 14, 202736
NCT07551349Clear-cell metastatic renal cell carcinoma · China2RecruitingBeijing BiotechApr 14, 202736
NCT07551336Glioma · China1RecruitingBeijing BiotechApr 14, 202736
NCT07523542Lupus Erythematosus, Systemic · China2RecruitingBeijing BiotechMar 14, 202724
NCT07523529Neoplasm Metastasis · China2RecruitingBeijing BiotechApr 14, 202772
NCT07492628Urinary Bladder Neoplasms · China1RecruitingBeijing BiotechJun 14, 202742
NCT07480941Glioblastoma · China1RecruitingBeijing BiotechFeb 18, 202736
NCT07246304Small Cell Lung Carcinoma · ChinaEarly 1RecruitingTCRCure BiopharmaNov 30, 202724
NCT07149857Multiple Myeloma · United States, Australia, Spain2RecruitingJohnson & JohnsonApr 12, 202860
NCT07144462Autoimmune · ChinaEarly 1RecruitingNeukio Biotherapeutics (Shanghai)Jan 14, 20278
NCT07105176Advanced Non-Small Cell Lung Cancer · China1RecruitingHangzhou Huasai BiomedicineAug 30, 202712
NCT07085104Lupus Erythematosus, Systemic · United States, Canada1RecruitingAllogene TherapeuticsFeb 202866
NCT07115745Autoimmune Diseases · United States, Australia, Brazil and more1RecruitingBristol-Myers SquibbMar 15, 2029125
NCT06532643Lymphoma · ChinaEarly 1UNKNOWNShanghai First Song BiotechnologySep 1, 20259
NCT06532630B-Cell Malignancy · ChinaEarly 1RecruitingShanghai First Song BiotechnologySep 1, 20259
NCT06500273Lymphoma, Large B-Cell, Diffuse · United States, Australia, Canada and more2RecruitingAllogene TherapeuticsDec 2027250
NCT05727683Precursor Cell Lymphoblastic Leukemia-Lymphoma · China1RecruitingShanghai Ming Ju BiotechnologyOct 31, 202333
NCT05714345Recurrence · United States, Belgium2TerminatedAllogene TherapeuticsFeb 20, 20242
NCT04825496Recurrence · China1RecruitingShanghai Unicar-Therapy Bio-medicine TechnologyDec 31, 202318
NCT04735471Lymphoma, Follicular · United States1TerminatedAdicet TherapeuticsFeb 3, 202534
NCT04637763Lymphoma, Non-Hodgkin · United States, Australia, Israel1Active, not recruitingCaribou BiosciencesSep 11, 202572
NCT04030195Lymphoma, Non-Hodgkin · United States2CompletedPrecision BioSciencesJun 24, 202118
NCT03318861Multiple Myeloma · United States1TerminatedGilead SciencesDec 17, 201817
NCT02876978Lung Squamous Cell Carcinoma · China1UNKNOWNCARsgen TherapeuticsOct 201720
NCT02533401Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Venezuela2CompletedHoffmann-La RocheDec 201434
NCT01679041Multiple Sclerosis · United States2TerminatedSeah Lim M.D.Nov 20131
NCT01292603Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Australia, Brazil and more1CompletedHoffmann-La RocheMay 7, 2014240
NCT01283386Leukemia, Lymphocytic, Chronic, B-Cell · Russian Federation4TerminatedHoffmann-La RocheMar 16, 201626
NCT01271010Leukemia, Lymphocytic, Chronic, B-Cell · Russian Federation4TerminatedHoffmann-La RocheMay 4, 201689
NCT01263704Leukemia, Lymphocytic, Chronic, B-Cell · Israel2CompletedHoffmann-La RocheApr 3, 201742
NCT00625430Prostatic Neoplasms · Australia1UNKNOWNBiotech Equity Partners PtyDec 201218
NCT00545714Leukemia, Lymphocytic, Chronic, B-Cell · Spain2CompletedHoffmann-La RocheMay 20, 201686

How it is read

Names in the registry

  • “Fludarabine”, 40 entries
  • “Cyclophosphamide,Fludarabine”, 4 entries
  • “TC-D101 CAR-T”, 1 entry
  • “CD19-targeted Chimeric Antigen Receptor (CAR) T Cells”, 1 entry
  • “fludarabine, rituximab, pixantrone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.